Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives $20.25 Average Target Price from Analysts

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) has received an average rating of “Hold” from the fourteen analysts that are currently covering the stock, Marketbeat Ratings reports. Thirteen research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $20.25.

Several equities analysts have commented on FUSN shares. SVB Leerink reaffirmed a “market perform” rating and issued a $21.00 price objective (up previously from $17.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Truist Financial reissued a “hold” rating and issued a $21.00 price objective (up from $11.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Brookline Capital Management downgraded Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Jonestrading restated a “hold” rating on shares of Fusion Pharmaceuticals in a research report on Wednesday, March 20th. Finally, Wedbush cut Fusion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $24.00 target price for the company. in a research note on Tuesday, March 19th.

Fusion Pharmaceuticals Price Performance

NASDAQ FUSN opened at $21.24 on Monday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -14.45 and a beta of -0.72. The company has a debt-to-equity ratio of 0.16, a quick ratio of 15.01 and a current ratio of 15.01. The stock has a 50-day moving average of $15.67 and a 200 day moving average of $9.63. Fusion Pharmaceuticals has a one year low of $2.31 and a one year high of $21.55.

Fusion Pharmaceuticals (NASDAQ:FUSN) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. On average, sell-side analysts forecast that Fusion Pharmaceuticals will post -1.46 EPS for the current year.

Institutional Trading of Fusion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in FUSN. Federated Hermes Inc. raised its stake in shares of Fusion Pharmaceuticals by 94.1% during the 1st quarter. Federated Hermes Inc. now owns 3,055,037 shares of the company’s stock worth $23,738,000 after buying an additional 1,481,037 shares in the last quarter. UBS Group AG raised its position in Fusion Pharmaceuticals by 45,219.1% in the first quarter. UBS Group AG now owns 21,300 shares of the company’s stock valued at $165,000 after purchasing an additional 21,253 shares during the period. Millennium Management LLC purchased a new stake in shares of Fusion Pharmaceuticals during the second quarter worth about $29,000. Renaissance Technologies LLC purchased a new stake in shares of Fusion Pharmaceuticals during the third quarter worth about $51,000. Finally, Citadel Advisors LLC bought a new stake in Fusion Pharmaceuticals in the third quarter valued at about $86,000. 72.85% of the stock is owned by hedge funds and other institutional investors.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.